Market Overview

Kyprolis Draws Focus Away From Amgen

Related AMGN
#PreMarket Primer: Tuesday, November 25: Violent Protests In Ferguson Following Grand Jury Decision
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer
The Tech Industry is Vanishing Before Our Eyes (Fox Business)
Related CELG
Celgene Receives Positive CHMP Opinion For OTEZLA, The First Oral PDE4 Inhibitor For The Treatment Of Patients With Psoriasis And Psoriatic Arthritis
Which Mega Caps Are Buying Their Own Stock?
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

Bank of America Merrill Lynch biotech analyst Rachel McMinn commented on how an increased focus on Kyprolis Cardiovascular toxicities among centers have stolen the spotlight from Amgen (NASDAQ: AMGN).

RBC reported on Wednesday that Amgen's PCSK9 inhibitor has a 75 percent probability that the data will be positive after talking with senior management. Earlier, Amgen announced that the PCSK9 inhibitor reduced LDL- C in a 52-week study. The FDA said last week that outcome trials are not needed for PCSK9 approval.

McMinn examined on Friday Krypolis cardiovascular toxicities among centers with extensive treatment experience and noted, "irreversible proteasome binding potentially leads to differential toxicity vs. Velcade."

The analyst added that the studies are looking at reserving Krypolis, Revlimid, and dex for high-risk myeloma. The report noted that Revlimid and dex may be the key backbone of front-line myeloma therapy.

Amgen shares were down as much as 4.2 percent on Thursday. In e-mailed statement calls, Amgen wrote that the earlier Bank of America Merrill Lynch comments on Krypolis were misleading and "post-marketing reporting and on-going clinical trial data have not revealed any new safety concerns."

The company said that CELG “made no representation” of CV event rates “being any different than what is already included in the Kyprolis label” and that data monitoring committees have recommended continuing Phase 3 studies.

Celgene closed at $158.61 on Thursday and is currently up 2.53 percent. Amgen closed at $112.25 Thursday and shares are currently trading slightly up at 0.24 percent.

Latest Ratings for AMGN

DateFirmActionFromTo
Oct 2014CitigroupMaintainsBuy
Oct 2014Credit SuisseMaintainsNeutral
Oct 2014NomuraUpgradesNeutralBuy

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill Lynch Rachel McMinn RBCAnalyst Color Analyst Ratings Best of Benzinga

 

Related Articles (AMGN + CELG)

Around the Web, We're Loving...

Get Benzinga's Newsletters